ATE554091T1 - Aminotetrahydropyrane als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes - Google Patents

Aminotetrahydropyrane als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes

Info

Publication number
ATE554091T1
ATE554091T1 AT07754011T AT07754011T ATE554091T1 AT E554091 T1 ATE554091 T1 AT E554091T1 AT 07754011 T AT07754011 T AT 07754011T AT 07754011 T AT07754011 T AT 07754011T AT E554091 T1 ATE554091 T1 AT E554091T1
Authority
AT
Austria
Prior art keywords
aminotetrahydropyrans
dipeptidylpeptidase
diabetes
inhibitors
prevention
Prior art date
Application number
AT07754011T
Other languages
English (en)
Inventor
Tesfaye Biftu
Ann Weber
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE554091T1 publication Critical patent/ATE554091T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT07754011T 2006-03-28 2007-03-26 Aminotetrahydropyrane als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes ATE554091T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78651806P 2006-03-28 2006-03-28
US83812206P 2006-08-16 2006-08-16
PCT/US2007/007434 WO2007126745A2 (en) 2006-03-28 2007-03-26 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes

Publications (1)

Publication Number Publication Date
ATE554091T1 true ATE554091T1 (de) 2012-05-15

Family

ID=38521359

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07754011T ATE554091T1 (de) 2006-03-28 2007-03-26 Aminotetrahydropyrane als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes

Country Status (22)

Country Link
US (1) US7678905B2 (de)
EP (1) EP2001883B1 (de)
JP (1) JP5229706B2 (de)
KR (1) KR20090005306A (de)
AR (1) AR059984A1 (de)
AT (1) ATE554091T1 (de)
AU (1) AU2007243631B2 (de)
BR (1) BRPI0709141A2 (de)
CA (1) CA2646962C (de)
CR (1) CR10343A (de)
DO (1) DOP2007000051A (de)
EA (1) EA200870380A1 (de)
EC (1) ECSP088765A (de)
GT (1) GT200800184A (de)
MA (1) MA30333B1 (de)
MX (1) MX2008012490A (de)
NO (1) NO20084508L (de)
PE (1) PE20071104A1 (de)
SV (1) SV2008003045A (de)
TN (1) TNSN08367A1 (de)
TW (1) TW200806669A (de)
WO (1) WO2007126745A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910596B2 (en) 2006-02-15 2011-03-22 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
CA2652367A1 (en) * 2006-05-16 2007-11-29 Merck & Co., Inc. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
CA2668662A1 (en) 2006-11-14 2008-05-22 Merck & Co., Inc. Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2009014676A1 (en) * 2007-07-23 2009-01-29 Merck & Co., Inc. Novel crystalline form of a dihydrochloride salt of a dipeptidyl peptidase-iv inhibitor
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009025784A1 (en) 2007-08-21 2009-02-26 Merck & Co., Inc. Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US7902376B2 (en) 2008-01-23 2011-03-08 Merck Sharp & Dohme Corp. Process for preparing chiral dipeptidyl peptidase-IV inhibitor intermediates
JO2870B1 (en) 2008-11-13 2015-03-15 ميرك شارب اند دوهم كورب Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
KR20120092096A (ko) * 2009-09-02 2012-08-20 머크 샤프 앤드 돔 코포레이션 당뇨병의 치료 또는 예방을 위한 디펩티딜 펩티다제-iv 억제제로서의 아미노테트라히드로피란
JP2013505290A (ja) * 2009-09-23 2013-02-14 ファイザー・インク Gpr119調節因子
US8716482B2 (en) 2009-09-25 2014-05-06 Merck Sharp & Dohme Corp. Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
WO2011103256A1 (en) 2010-02-22 2011-08-25 Merck Sharp & Dohme Corp. Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8980929B2 (en) 2010-05-21 2015-03-17 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012078448A1 (en) 2010-12-06 2012-06-14 Schering Corporation Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
AU2012275638A1 (en) 2011-06-29 2013-11-14 Merck Sharp & Dohme Corp. Process for preparing chiral dipeptidyl peptidase-IV inhibitors
US9051329B2 (en) 2011-07-05 2015-06-09 Merck Sharp & Dohme Corp. Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9073930B2 (en) 2012-02-17 2015-07-07 Merck Sharp & Dohme Dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2014018350A1 (en) 2012-07-23 2014-01-30 Merck Sharp & Dohme Corp. Treating diabetes with dipeptidyl peptidase-iv inhibitors
EP2874626A4 (de) 2012-07-23 2016-03-23 Merck Sharp & Dohme Behandlung von diabetes mit dipeptidylpeptidase-iv-hemmern
TWI500613B (zh) * 2012-10-17 2015-09-21 Cadila Healthcare Ltd 新穎之雜環化合物
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
CN105085528A (zh) * 2014-05-15 2015-11-25 成都贝斯凯瑞生物科技有限公司 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物
WO2015192701A1 (zh) * 2014-06-17 2015-12-23 四川海思科制药有限公司 氨基吡喃环衍生物及其组合物和应用
JP6574474B2 (ja) 2014-07-21 2019-09-11 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. キラルジペプチジルペプチダーゼ−iv阻害剤の製造方法
SG11201703557UA (en) * 2014-10-31 2017-06-29 Univ East China Science & Tech Six-membered ring benzo derivatives as dpp-4 inhibitor and use thereof
CN105985357A (zh) * 2015-02-12 2016-10-05 北京赛林泰医药技术有限公司 取代的氨基六元饱和杂脂环类长效dpp-iv抑制剂
ES2805743T3 (es) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes
WO2017093209A1 (en) 2015-12-03 2017-06-08 F.I.S. - Fabbrica Italiana Sintetici S.P.A. Process for preparing aminotetrahydropyrans
WO2017202357A1 (zh) * 2016-05-25 2017-11-30 四川海思科制药有限公司 一种三氟甲基取代的吡喃衍生物的制备方法
CN108699068B (zh) * 2016-05-25 2021-01-08 四川海思科制药有限公司 一种三氟甲基取代的吡喃衍生物制备方法
PT3448859T (pt) 2017-03-20 2019-10-25 Forma Therapeutics Inc Composições de pirrolopirrole como ativadores de piruvato quinase (pkr).
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
CN114615977B (zh) 2019-09-19 2025-01-14 诺沃挪第克健康护理股份公司 丙酮酸激酶r(pkr)活化组合物
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114961A (en) * 1989-06-08 1992-05-19 Merck & Co., Inc. 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
DE60221983T2 (de) * 2001-06-27 2008-05-15 Smithkline Beecham Corp. Fluorpyrrolidine als dipeptidyl-peptidase inhibitoren
JP2007513058A (ja) * 2003-09-08 2007-05-24 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
US7482336B2 (en) * 2004-06-21 2009-01-27 Merck & Co., Inc. Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2006058064A2 (en) 2004-11-29 2006-06-01 Merck & Co., Inc. Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US7884104B2 (en) 2004-10-01 2011-02-08 Merck Sharp & Dohme Corp. Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2006127530A2 (en) 2005-05-25 2006-11-30 Merck & Co., Inc. Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
CA2619111C (en) 2005-08-26 2013-04-09 Merck & Co., Inc. Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US7910596B2 (en) * 2006-02-15 2011-03-22 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
CA2652367A1 (en) * 2006-05-16 2007-11-29 Merck & Co., Inc. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
CA2668662A1 (en) * 2006-11-14 2008-05-22 Merck & Co., Inc. Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes

Also Published As

Publication number Publication date
JP5229706B2 (ja) 2013-07-03
CA2646962A1 (en) 2007-11-08
MX2008012490A (es) 2008-10-10
ECSP088765A (es) 2008-10-31
KR20090005306A (ko) 2009-01-13
US20070232676A1 (en) 2007-10-04
WO2007126745A3 (en) 2007-12-21
AR059984A1 (es) 2008-05-14
PE20071104A1 (es) 2007-12-29
AU2007243631B2 (en) 2011-11-24
EP2001883A2 (de) 2008-12-17
BRPI0709141A2 (pt) 2011-06-28
SV2008003045A (es) 2009-11-09
US7678905B2 (en) 2010-03-16
EA200870380A1 (ru) 2009-02-27
EP2001883B1 (de) 2012-04-18
GT200800184A (es) 2011-09-05
WO2007126745A2 (en) 2007-11-08
TNSN08367A1 (en) 2009-12-29
MA30333B1 (fr) 2009-04-01
DOP2007000051A (es) 2007-12-15
TW200806669A (en) 2008-02-01
CR10343A (es) 2008-10-29
CA2646962C (en) 2011-06-21
AU2007243631A1 (en) 2007-11-08
NO20084508L (no) 2008-10-27
JP2009531437A (ja) 2009-09-03

Similar Documents

Publication Publication Date Title
ATE554091T1 (de) Aminotetrahydropyrane als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes
EP1996182A4 (de) Krebsbehandlung mit gamma-sekretasehemmern
EP2313146A4 (de) Vorrichtungen zur behandlung von vaskulärem aneurysma
AP2010005480A0 (en) Small molecule inhibitors for the treatment or prevention of denque virus infection.
DK1942898T4 (da) Dipeptidylpeptidase-inhibitorer til behandling af diabetes
EP3895670C0 (de) Vorrichtung zur behandlung von adipositas
ATE550333T1 (de) 4-benzylamino-1-carboxyacyl-piperidinderivate als cetp-hemmer zur behandlung von krankheiten wie hyperlipidämie oder arteriosklerose
BRPI0920104A2 (pt) tratamento de soluções ou de águas residuais
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
EP2061385A4 (de) Gefässbehandlungsgerät
EP2175873A4 (de) Behandlung von angstzuständen
EP2282737A4 (de) Zusammensetzungen und verfahren zur behandlung von parodontalerkrankung mit clonidin, sulindac und/oder fluocinolon
PT2046324T (pt) Tratamento e prevenção de mucosite por derivados de antocianidina
DK2034830T3 (da) Anti-vla-1-antistof til behandling af slagtilfælde
ZA200807488B (en) Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP2135858A4 (de) Zusammensetzung zur behandlung von infektionserkrankungen
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
EP2091530A4 (de) Zusammensetzung zur hemmung von nadph-oxidaseaktivität
EP2249765A4 (de) Dapson zur behandlung von rosascea
EP2274245A4 (de) Phytosystem zur behandlung von abwasser
BRPI0822129A2 (pt) Inibidores de aldh-2c no tratamento de vício.
EP1905452A4 (de) Wirkstoff zur prävention oder behandlung von glaukomen
ATE516805T1 (de) Medikament zur behandlung von endometriose
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen